Identifying potential prescription drug product hopping-Reference-Cited by-同舟云学术

Identifying potential prescription drug product hopping

Published:2021-04 Issue:4 Volume:39 Page:414-417
ISSN:1087-0156
Container-title:Nature Biotechnology
language:en
Short-container-title:Nat Biotechnol

Author:

Gowda Vrushab,Beall Reed F.^ORCID,Kesselheim Aaron S.,Sarpatwari Ameet^ORCID

Funder

Work funded by Arnold Ventures. Dr. Sarpatwari and Kesselheim’s research also supported by the Harvard-MIT Center for Regulatory Science

Publisher

Springer Science and Business Media LLC

Subject

Biomedical Engineering,Molecular Medicine,Applied Microbiology and Biotechnology,Bioengineering,Biotechnology

Link

http://www.nature.com/articles/s41587-021-00877-9.pdf

Reference15 articles.

1. Feldman, R. J. Law Biosci. 5, 590–647 (2018).

2. Beall, R. F., Kesselheim, A. S. & Sarpatwari, A. J. Manag. Care Spec. Pharm 25, 218–224 (2019).

3. Gladstone, J. P. & Gawel, M. Drugs 63, 2285–2305 (2003).

4. Harris, G. Prilosec’s maker switches users to Nexium, thwarting generics. The Wall Street Journal (6 June 2002); http://www.wsj.com/articles/SB1023326369679910840

5. Gellad, W. F., Choi, P., Mizah, M., Good, C. B. & Kesselheim, A. S. Am. J. Manag. Care 20, e90–e97 (2014).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Federal Trade Commission Actions on Prescription Drugs, 2000-2022;JAMA;2024-06-18

2. Understanding ‘Evergreening’: Making Minor Modifications Of Existing Medications To Extend Protections;Health Affairs;2022-06-01

3. The $5 Billion Hop: Glatiramer Acetate and the US Patent System;Journal of Law, Medicine & Ethics;2022

4. Combination therapy patents: a new front in evergreening;Nature Biotechnology;2021-12